Loading
Led POLO, the first biomarker-driven trial in pancreatic cancer, which brought olaparib to BRCA carriers.
Talia Golan was principal investigator and first author of POLO, which showed maintenance olaparib nearly doubles progression-free survival in germline BRCA-mutant metastatic pancreatic cancer after platinum chemotherapy, the first targeted therapy approval in the disease. She directs the pancreatic cancer centre at Sheba and works on organoid-guided therapy and DNA damage response combinations.
The current honest statement of where early detection stands: no blood test is ready, and the research is about finding the threshold at which to operate.
This is the European standard the UK and NHS page for pancreatic cancer is compared against; NICE guideline NG85 (2018) covers the same ground with an older evidence base and a narrower set of funded drugs.
Olaparib maintenance remains a standard option because of its progression-free benefit, tolerability and long-term survivors, but patients should know that it has not been shown to extend average survival.
Germline testing for every pancreatic cancer patient, platinum first line for BRCA carriers, and olaparib maintenance for those who respond are all downstream of POLO.
It fixed the working numbers for a comprehensive panel in pancreatic cancer: a hit worth acting on in about one patient in six, most of it in repair genes and the KRAS wild-type minority.
The retrospective platinum signal that made platinum-based first-line chemotherapy the standard for BRCA carriers and set POLO's design of olaparib after platinum.
Shares POLO final overall survival: maintenance olaparib versus placebo in germline BRCA-mutated metastatic pancreatic cancer, POLO: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer, POLO, Olaparib and the tag pancreatic.
Shares POLO final overall survival: maintenance olaparib versus placebo in germline BRCA-mutated metastatic pancreatic cancer, Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers, POLO: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer, BRCA or PALB2-mutant pancreatic ductal adenocarcinoma and the tag brca.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.
Shares Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pancreatic.
Shares PARP, PARP inhibitors, BRCA1 / BRCA2 (HRD) and the tag parp.